Loading...

Archive

    25 October 2024, Volume 14 Issue 5 Previous Issue    Next Issue

    For Selected: Toggle Thumbnails
    Explore the Mechanism of Paeoniae Radix Alba Delaying Alzheimer's Disease Based on Network Pharmacology and Molecular Docking
    ZHAO Yu-ting, YIN Hong-yan, GUO Chun-yan
    2024, 14 (5):  1.  DOI: 10.3969/j.issn.2095-1396.2024.05.001
    Abstract ( 6 )   PDF (2581KB) ( 1 )  
    Objective: To predict the active components, potential targets and mechanisms of Paeoniae Radix Alba in the prevention and treatment of Alzheimer's disease (AD) by network pharmacology and molecular docking strategy, so as to provide evidence for the application of Paeoniae Radix Alba in the prevention and treatment of AD. Methods: TCMSP database was used to query the chemical constituents and targets of Paeonia lactiflora and looked up the targets of AD-related proteins through Gene Cards database. Then, the targets of Paeoniae Radix Alba and AD were entered into Venny 2.1 website to get the intersection targets of root of herbaceous peony and AD, and made Venny map. The intersection targets were imported into Multiple proteins under String database, and the PPI network map was drawn. After importing the intersection targets into Cytoscape, the degree value was analyzed, and the top ranked compounds and targets were screened out. Then the intersection targets were imported into David website to conduct GO and KEGG analysis. Finally, the molecular docking technology was used to verify the Paeoniae Radix Alba in preventing and treating AD. Results: A total of 15 chemical constituents were screened from Paeoniae Radix Alba with 208 cross targets. The terms of GO and KEGG analysis mainly involved in RNA and DNA defect, protein binding, oxidative stress, inflammatory reaction and cancer-related pathways. The results of molecular docking showed that paeoniflorin (PF), albiflorin (AL) and Catechin [(+)-catechin, CT] bound SRC, EGFR and HSP90AA1 well, respectively. Conclusion: Paeoniae Radix Alba can prevent and treat AD by inhibiting the deposition of Aβ protein and the aggregation of Tau protein, inhibiting inflammatory reaction and oxidative stress, and protecting neurons. The underlying molecular mechanisms may be that PF, AL and CT down-regulates SRC, up-regulates HSP90AA1 and down-regulates EGFR. This paper provides a new idea for the clinical application of Paeoniae Radix Alba in the prevention and treatment of AD.
    Related Articles | Metrics
    Three-Dimensional Quantitative Structure-Activity Relationship Study of Quinazoline-Based FGFR4 Inhibitors
    LU Chen-xuan, CHEN Zhuo-zhuo, LI Guo-feng, LIU Xing-yuan, MENG Hong, QIN Yu-han, LI Ya-xin
    2024, 14 (5):  10.  DOI: 10.3969/j.issn.2095-1396.2024.05.002
    Abstract ( 4 )   PDF (2277KB) ( 0 )  
    Objective: The abnormal activation of the Fibroblast Growth Factor 19(FGF19) and Fibroblast Growth Factor Receptor 4 (FGFR4) signaling pathway promotes the proliferation of hepatocellular carcinoma cells, making FGFR4 one of the key targets for treating hepatocellular carcinoma. This study aims to elucidate the relationship between the structure and activity of quinazoline-based FGFR4 inhibitors using a three-dimensional quantitative structureactivity relationship (3D-QSAR) approach. Methods: 36 compounds were randomly divided into a training set and a test set. 3D-QSAR models were constructed using Comparative Molecular Field Analysis (CoMFA) and Comparative Molecular Similarity Indices Analysis (CoMSIA). Results: The cross-validation coefficients (q²) of the CoMFA and CoMSIA models were 0.735 and 0.680, respectively, and the fitting validation coefficients (r²) were 0.974 and 0.981, respectively. The predicted values of the two models were generally consistent with the experimental values,indicating that the models have predictive ability and good robustness. Conclusion: The contour maps illustrate the effects of different field effects on compound activity, providing insights for the design of novel quinazoline-based FGFR4 inhibitors.
    Related Articles | Metrics
    Network Pharmacology Study of Sini SAN in the Treatment of Post-Stroke Depression
    ZHOU Xin-mei, ZHU Li-ping
    2024, 14 (5):  19.  DOI: 10.3969/j.issn.2095-1396.2024.05.003
    Abstract ( 5 )   PDF (4308KB) ( 0 )  
    Objective: To explore the molecular mechanism of Sini SAN in the treatment of post-stroke depression based on network pharmacology and molecular docking techniques. Methods: Active ingredients and therapeutic targets in Sini SAN were searched through TCMSP database. Gene targets of post-stroke depression were collected using GeneCards, OMIM and PharmGkb databases. The intersection targets were selected as potential targets and imported into String database to establish protein interaction (PPI) network. Network topology analysis by Cytoscape software. PPI targets were introduced into R for gene ontology (GO) function and Kyoto Encyclopedia of Genomes (KEGG) pathway enrichment analysis. The “pathway-target” network was constructed and the key targets were screened, and the AMDock platform was used to interconnect the target with the active ingredient to screen the potential pharmacodynamic ingredient.Results: 104 kinds of drug chemical components, 235 targets and 1 001 disease target genes of Sini SAN were obtained from the database, including 7 kinds of drug core components and 77 overlapping genes with diseases. Through software analysis, MMP9, AKT1, IL-10, ESR1, IL-6, HIF1A, IL-1B, CASP3 and TNF were the core genes. GO enrichment analysis showed that it was mainly through the molecular functions of protease binding, nuclear receptor activity, cytokine activity, estrogen response element binding, etc., in the membrane raft, membrane microregion, plasma membrane raft, Bcl-2 family protein complex, plasma membrane lateral, neuron cell body, endoplasmic reticulum cavity and other action sites. The reaction to the decrease of oxygen content, the regulation of apoptosis signaling pathway, the reaction to lipopolysaccharide and other processes play a role. KEGG analysis showed AGE-RAGE signaling pathway, p53 signaling pathway, TNF signaling pathway, estrogen signaling pathway, HIF-1 signaling pathway and other major signaling pathways. Conclusion: Sini SAN may act on MMP9, IL-6, HIF1A, IL-1B, CASP3 and other potential targets through various active ingredients such as quercetin, luteolin, kaempferol, chenetin, naringin, isorhamnetin, and ononin. It mediates AGE-RAGE signaling pathway, estrogen signaling pathway, HIF-1 signaling pathway and other signaling pathways to play an effective role.
    Related Articles | Metrics
    Exploring the Medication Pattern of Huang Xili in Treating Chronic Pelvic Inflammatory Disease Based on the Auxiliary Platform of Traditional Chinese Medicine Inheritance
    SHEN Yan-hui, HONG Li-mei, CHEN Zhi-ying, HUANG Xi-li
    2024, 14 (5):  31.  DOI: 10.3969/j.issn.2095-1396.2024.05.004
    Abstract ( 6 )   PDF (1403KB) ( 0 )  
    Objective: To explore the medication patterns of Professor Huang Xili in the treatment of chronic pelvic inflammatory disease (CPID). Methods: From January 2021 to December 2022, the prescriptions of Professor Huang Xili’s outpatient treatment of chronic pelvic inflammatory disease (CPID) were collected, and the TCM inheritance assistance platform (V2.5) software was used to analyze and summarize the medication rules. Results: A total of 974 prescriptions were collected, involving 91 kinds of traditional Chinese medicine. The four kinds of qi were mainly cold, followed by warm. Bitter taste was the most, spicy taste was the second. The frequency of hepatic channel was the highest, followed by spicy heart channel and spleen channel. A total of 38 pairs of common drug combinations were obtained by association rule analysis, and 6 potential new prescriptions were obtained based on entropy clustering method. Conclusion: Professor Huang Xili’s main treatment methods for chronic pelvic inflammatory disease include clearing heat, detoxifying, removing dampness, nourishing blood, promoting blood circulation, removing blood stasis, soothing the liver, regulating qi, and relieving pain. This reflects Professor Huang’s treatment philosophy of putting the disease first, treating from the perspective of the internal organs, and balancing the elimination of evil and the strengthening of the body.
    Related Articles | Metrics
    The Effects of A Combination Therapy of Methylprednisolone and Doxycycline on Inflammatory Factors and Oxidative Stress Indicators in Children with Mycoplasma Pneumoniae Pneumonia
    SHENG Wen-cai, ZHOU Yue
    2024, 14 (5):  37.  DOI: 10.3969/j.issn.2095-1396.2024.05.005
    Abstract ( 9 )   PDF (1033KB) ( 0 )  
    Objective: To analyze the effectiveness of a combination therapy of methylprednisolone and doxycycline in children with Mycoplasma pneumoniae pneumonia and to explore its impact on inflammatory factors and oxidative stress indicators. Methods: A total of 200 children with Mycoplasma pneumoniae pneumonia treated in our hospital from May 2021 to May 2023 were selected and randomly divided into two groups. The control group (n=100) received doxycycline monotherapy, while the observation group (n=100) received a combination therapy of methylprednisolone and doxycycline. The therapeutic effects, levels of inflammatory factors, oxidative stress levels, and adverse drug reactions were compared between the two groups. Results: After a two-week treatment period, the overall effective rate of treatment in the observation group was higher than that in the control group. Levels of inflammatory factors (CRP,TNF-α, IL-8) in the observation group were lower than those in the control group. Oxidative stress indicators showed that LPO levels were lower, while ALB and TBIL levels were higher in the observation group compared to the control group. These differences were statistically significant (P<0.05). However, there was no statistical significance in the comparison of adverse drug reactions between the two groups (P>0.05). Conclusion: The combination therapy of methylprednisolone and doxycycline effectively regulates the levels of inflammatory factors and oxidative stress indicators in children with Mycoplasma pneumoniae pneumonia, achieving remarkable therapeutic effects with high safety.
    Related Articles | Metrics
    Protective Effect of Dexmedetomidine Combined with Lidocaine on Brain in Patients Undergoing Craniocerebral Tumor Surgery
    SUN Qing-tian
    2024, 14 (5):  42.  DOI: 10.3969/j.issn.2095-1396.2024.05.006
    Abstract ( 3 )   PDF (1019KB) ( 0 )  
    Objective: To investigate the protective effect of dexmedetomidine combined with lidocaine on brain in patients undergoing craniocerebral tumor surgery. Methods: 60 patients with craniocerebral tumor surgery were divided into lidocaine group, dexmedetomidine group and combined group according to different anesthesia schemes, 20 cases in each group. Rocuronium bromide, sufentanil, propofol and midazolam were used for anesthesia induction. Dexmedetomidine group was given continuous infusion of 0.4 μg·kg-1·h-1 dexmedetomidine during anesthesia maintenance. Lidocaine group was given continuous infusion of 2.0 mg·kg- 1·h-1 lidocaine during anesthesia maintenance. Dexmedetomidine 0.2 μg·kg-1·h-1 and lidocaine 1.0 mg·kg-1·h-1 were continuously infused during anesthesia maintenance in the combined group.The levels of serum neuron-specific enolase (NSE), S-100β, inflammatory factors, cognitive function and neurological function were measured. Results: There was no significant difference in serum NSE and S-100β levels among the three groups before administration (T0) (P>0.05). At T1, T2 and T3, the serum NSE and S-100β levels in the lidocaine group were lower than those in the dexmedetomidine group (P<0.05), and the combined group was lower than the lidocaine group (P<0.05). There was no significant difference in the levels of IL-6, TNF-α, hs-CRP and NFA score among the three groups before operation (P>0.05). The levels of IL-6, TNF-α, hs- CRP and NFA score in the lidocaine group were lower than those in the dexmedetomidine group (P<0.05), and those in the combined group were lower than those in the lidocaine group (P<0.05). There was no significant difference in MMSE score among the three groups before operation (P>0.05). After operation, the MMSE score of the lidocaine group was higher than that of the dexmedetomidine group (P<0.05), and the combined group was higher than the lidocaine group (P<0.05). Conclusion: Lidocaine combined with dexmedetomidine can significantly reduce the levels of nerve injury markers and inflammatory factors in craniocerebral tumor surgery, improve postoperative cognitive function and neurological function, and have potential advantages in brain protection.
    Related Articles | Metrics
    Recent Progress in the Metabolomics of Alzheimer's Disease
    ZHANG Xin, YAO Si-fan, MA Meng-fan, SHEN Li-xia
    2024, 14 (5):  47.  DOI: 10.3969/j.issn.2095-1396.2024.05.007
    Abstract ( 9 )   PDF (983KB) ( 1 )  
    Alzheimer's disease is a complex neurodegenerative disorder whose exact etiology is still not fully understood. In recent years, the application of metabolomics has provided new perspectives to unravel the complex biological mechanisms of Alzheimer's disease. By quantitatively analyzing a comprehensive range of metabolites in biological samples, researchers are able to identify metabolic changes associated with Alzheimer's disease, providing data to support the exploration of potential diagnostic markers and therapeutic targets. This paper reviews research advances in metabolomics in revealing metabolic changes, identifying biomarkers, and detection tools for Alzheimer's disease. Metabolomics studies have confirmed the presence of reduced brain energy metabolism, abnormal membrane phospholipid metabolism, and imbalances in pathways related to lipid, amino acid, and choline metabolism in patients with AD. These findings emphasize the importance of metabolomics in AD and provide valuable information for future research directions and clinical diagnosis.
    Related Articles | Metrics
    Research Progress of Dexmedetomidine in Postoperative Delirium in Elderly Patients
    ZHANG Yu-xi, YAO Jie
    2024, 14 (5):  57.  DOI: 10.3969/j.issn.2095-1396.2024.05.008
    Abstract ( 3 )   PDF (933KB) ( 0 )  
    Postoperative delirium (POD) is a common complication after surgical anesthesia in elderly patients, especially after major surgery or emergency surgery, which interferes with the recovery process of patients and the prognosis of the primary disease, and may cause new complications to prolong the hospitalization cycle, increase the fatality rate and increase the medical cost of patients. Because the mechanism of POD is not clear, there is a lack of effective prevention measures. Recent studies have shown that Dexmedetomidine (DEX), as a highly selective α2 adrenergic receptor agonist, has shown certain advantages in POD prevention and treatment. In this paper, the related mechanisms and risk factors of POD, the clinical studies of dexmedetomidine in the prevention and treatment of POD in elderly patients and its potential mechanisms were reviewed, aiming to provide theoretical basis for clinical application.
    Related Articles | Metrics